Cypress inks $75M deal to acquire Proprius

Cypress Bioscience has inked a deal to buy Proprius Pharmaceuticals in a deal that starts out at $37.5 million up front and goes up to $75 million if its gamble on new diagnostic technology pays off. Proprius has been developing diagnostic tools for rheumatoid arthritis. According to Cypress' release, "the nearest-term commercial opportunities include an early RA prediction technology, which helps to determine the likelihood of developing RA in patients with Undifferentiated Arthritis, and a methotrexate polyglutamates monitoring assay, which helps physicians to optimize MTX therapy by providing insights on an individual's metabolism of MTX, which can vary greatly from patient to patient." Michael Walsh, Proprius' founder, president and chief executive, is assuming the job of executive vice president and chief commercial officer of the expanded company.

"We believe that this combination will allow us to bring a unique offering of therapeutics and personalized medicine laboratory services to physicians, one that addresses important unmet medical needs in the treatment of both fibromyalgia and rheumatoid arthritis," said Jay D. Kranzler, MD, PhD, Chairman and CEO of Cypress. 

- read the release

Related Articles:
Cypress shares soar on new pain data. Report
Cypress releases positive fibromyalgia data. Report
Cypress halts trial for sleep apnea therapy. Report

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.